BRUKER CORPORATION - 8-K Filing

Bruker Corporation announced on April 6, 2026, that Falko Busse, Ph.D., executive officer and President of Bruker BioSpin, will transition from his duties around May 1, 2026, with employment termination set for October 31, 2026. Dr. Busse and Bruker Switzerland AG entered into a separation agreement effective April 7, 2026. The agreement includes severance, a pro-rated bonus, and payout for unused vacation days, totaling approximately CHF 1,020,351, payable on the separation date. Dr. Busse will forfeit any unvested equity awards. The agreement also includes customary restrictive covenants and confidentiality obligations. This filing is an 8-K, reporting a change in corporate governance and management.